ARCHIVES

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

This article is from The Cancer Letter archive.

Vol. 32 No. 07 | February 24, 2006

Download PDF Visit The Full Archive

Related Articles

Obese Men With Benign Biopsy At High Risk for Prostate Cancer

April 26, 2013

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

October 22, 2004

In Brief: House Appropriations Bill Marked Up, Lid Clamped On; Wells Named DCT Board Chairman

July 6, 1984

DCCP To Have Board Of Scientific Counselors

September 1, 1978

Drug Development Effort Criticized

April 18, 1975

MSKCC oncologist settles insider trading case with SEC.

November 11, 2005